{"id":"W4224982972","doi":"10.1016/s1470-2045(22)00212-1","title":"Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; Chugai Pharmaceutical; MSD Australia; EMD Serono; Genentech; Takeda Pharmaceuticals U.S.A.; Merck Sharp and Dohme; Astellas Pharma; Eisai; Pfizer; Incyte; Ipsen; Exelixis; Kissei; Bayer Fund; Sanofi; GlaxoSmithKline; Merck; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb; Eli Lilly and Company; EUSA Pharma; AstraZeneca; Amgen; Alexion Pharmaceuticals; Astellas Pharma US","keywords":"Pembrolizumab; Lenvatinib; Sunitinib; Renal cell carcinoma; Everolimus; Kidney cancer; Phases of clinical research; Carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001404638,0.001224057,0.002907585,0.0003377504,0.0004109042,0.00102506,0.0007617239,0.001470468,0.003588651],"category_scores_gemma":[0.001413764,0.0006002511,0.00358059,0.0005092157,0.0009705705,0.001025648,0.0005062131,0.003133526,0.0004311056],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001257046,"about_ca_system_score_gemma":0.0009603584,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001784108,"about_ca_topic_score_gemma":0.00341581,"domain_scores_codex":[0.9991844,0.0004275237,0.00004874444,0.0001512552,0.00006550086,0.0001225899],"domain_scores_gemma":[0.9990028,0.0002871394,0.0002817258,0.0000529104,0.00005242805,0.0003229956],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9789904,0.004424158,0.002499362,0.0004287544,0.002100858,0.00002334344,0.00004369684,0.0004148262,0.001216048,0.00004171599,0.0003424322,0.009474326],"study_design_scores_gemma":[0.8788199,0.1051724,0.01308017,0.00003785167,0.001555545,0.00003507889,0.00004079235,0.0004433086,0.0002626257,0.0001321655,0.0003970733,0.00002308233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947477,0.00322176,0.0001227608,0.0003000101,0.0001777962,0.0004121638,0.0004113244,0.00001618645,0.0005903069],"genre_scores_gemma":[0.9962642,0.001138852,0.0003126859,0.0004034342,0.000190385,0.0005297591,0.0005378612,0.000005330112,0.0006175001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003588651,"threshold_uncertainty_score":0.01200521,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08879883769833696,"score_gpt":0.363652133835431,"score_spread":0.2748532961370941,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}